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This study was initiated to evaluate the long-term safety, tolerability and effect on seizure control of lamotrigine 
(Lamictal@) in paediatric patients with epilepsy. A total of 155 children (aged 2-19 years) with treatment-resistant 
epilepsy received add-on therapy or monotherapy lamotrigine for up to four years. Patients had already 
experienced benefit from lamotrigine treatment in an open one-year study before entering this open continuation 
study of up to three additional years of treatment. Overall, including both these studies, patients were treated with 
lamotrigine for 53-221 weeks, representing 417.9 patient-years of experience. The physician’s global assessment of
seizure control compared to the three-month period before lamotrigine treatment, indicated that seizure control 
was generally maintained during long-term lamotrigine treatment for up to four years. For 19 patients, the 
investigator recorded a subjective improvement in behaviour, alertness, seizure severity, quality of life and mobility 
with lamotrigine treatment, sometimes independent of seizure control. In total, 34 patients received lamotrigine 
monotherapy; 22 of these were maintained on lamotrigine monotherapy for at least one year. Lamotrigine was well 
tolerated. The majority of adverse experiences were classified by the’physician as being mild in intensity and only 
six patients (4%) withdrew from the study due to adverse experiences. 
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INTRODUCTION 
Lamotrigine (Lamictal@) is a broad-spectrum 
antiepileptic drug (AED) which acts primarily via 
a use-dependent blockade of voltage-sensitive 
sodium channels’ to stabilize the neuronal mem- 
brane and inhibit the release of excitatory 
neurotransmitters, principally glutamate. Lamo- 
trigine is effective as add-on therapy in adults 
with refractory partial and secondarily general- 
ized tonic-clonic seizures2V3 and has been shown 
to be at least as effective as carbamazepine4 or 
phenytoin5, but better tolerated when used as 
monotherapy in newly-diagnosed patients with 
epilepsy . 4*s In addition, lamotrigine has demon- 
strated efficacy in paediatric patients with 
treatment-resistant partial, myoclonic, absence, 
tonic and atonic seizures in trials lasting up to 12 
monthsGg. In view of the need for prolonged 
treatment of patients with epilepsy, it is important 
that the efficacy and tolerability of any AED 
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is maintained during long-term therapy. 
In this continuation study, the long-term safety 
and efficacy of lamotrigine were evaluated in 
paediatric patients who had already completed a 
12-month trial of lamotrigine as add-on therapy 
and who had shown benefit with acceptable 
tolerability in the initial study. The results of the 
initial 1Zmonth study have recently been 
publishedg. Some patients in the continuation 
study received lamotrigine monotherapy as a 
result of the successful withdrawal of previously 
prescribed AEDs. 
METHOD 
Patient population 
Following 12 months of treatment with lamo- 
trigine in a previous open trialg, patients with 
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refractory epilepsy treated successfully with lamo- 
trigine with or without other AEDs, were 
included in an international multicentre open 
continuation study of lamotrigine therapy. To be 
included, patients must have benefited from 
treatment with lamotrigine, with no unacceptable 
adverse experiences, during the previous 12- 
month open study. There were 155 patients from 
32 centres who received lamotrigine for up to an 
additional three years in this continuation study. 
The parent or guardian of the child had given 
written informed consent for participation in the 
initial 1Zmonth study with the understanding of 
the availability of a continuation phase should the 
child benefit from continued lamotrigine treat- 
ment. The study was approved by local ethics 
committees and was conducted in accordance 
with the declaration of Helsinki. 
Study design 
The screening visit for the continuation study 
generally utilized data from the last visit of the 
previous 1Zmonth trial. The daily dose of 
lamotrigine was the optimal dose determined 
individually for each patient in the previous 
1Zmonth study and was, in the first case, based 
on the patient’s concurrent antiepileptic medica- 
tion. The dose of lamotrigine was adjusted as 
required to improve efficacy or reduce any 
adverse effects. A twice-daily dosage regimen was 
generally used and, where possible, each dose 
consisted of a single tablet or capsule. 
There was no restriction to the number of 
concomitant AEDs used. Dosage reduction or 
withdrawal of co-medication was allowed, with 
appropriate adjustments to the lamotrigine dose 
where necessary. 
In this study, the final evaluation was carried 
out after either two or three years of additional 
treatment with lamotrigine. Alternatively, par- 
ticipation in the continuation study ceased when 
the patient met certain withdrawal criteria. These 
were: withdrawal of informed consent by the 
parent or guardian; development of severe or 
unacceptable adverse experiences (including bio- 
chemical or haematological abnormalities); lack 
of efficacy or any risk outweighing benefit from 
continued lamotrigine treatment; or evidence of 
serious non-compliance. In many cases, the 
decision was made to continue treatment with 
lamotrigine. If lamotrigine was discontinued, it 
was recommended that the dose was reduced to 
50% for two weeks and then to 25% for a further 
two weeks before finally stopping treatment. This 
was to decrease the likelihood of rebound 
seizures occurring. 
Assessment procedures 
The medical history of each patient had already 
been documented for the previous 1Zmonth 
study’. This included details of seizure aetiology, 
type and frequency, age at first seizure, and the 
occurrence of status epilepticus. For each patient, 
demographic data were recorded, detailing date 
of birth, sex, height and weight. Standard physical 
and neurological examinations, including fundos- 
copy were performed. In addition, haematologi- 
cal and biochemical assessments were conducted. 
Patients entering the continuation study after 
completing 48 weeks of lamotrigine therapy were 
seen at approximately six-month intervals, at 
weeks 72,96, 120, 144, 168 and 192 when seizure 
frequency, adverse experiences, height, weight, 
lamotrigine compliance and concurrent AED 
compliance were evaluated. The week numbers 
refer to the total weeks of treatment with 
lamotrigine, from the commencement of therapy 
and not from the commencement of the con- 
tinuation study. This implies that the first week of 
the study was after 48 weeks of lamotrigine 
therapy, that is after approximately one year. 
Seizure frequency was compared to a three- 
month historical baseline prior to lamotrigine 
treatment and was assessed on a scale of 1 to 7: 
1 = marked deterioration; 
2 = moderate deterioration; 
3 = mild deterioration; 
4 = no change; 
5 = mild improvement; 
6 = moderate improvement; 
7 = marked improvement. 
The total daily dose of lamotrigine over the 
previous two weeks and the dosage reduction or 
withdrawal of concomitant AED were recorded. 
Compliance with taking lamotrigine was recorded 
as excellent (100% compliance), good (SO-90%), 
poor (50-79%), unacceptable (~50%) or un- 
known. The assessment was made by the inves- 
tigator by discussion with the parent or guardian 
and by counting the returned capsules. 
Adverse experiences since the last documented 
visit were recorded with respect to intensity, 
seriousness, action taken and whether they were 
attributable to lamotrigine. Intensity was re- 
ported as mild, moderate or severe. Seriousness 
was classified as non-serious, serious or life- 
threatening. Each event was allocated to one of 
three categories: attributable to lamotrigine, not 
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attributable to lamotrigine, or unknown. Action 
taken was reported as none required, change in 
the study drug, treatment required or other. 
Other safety data were assessed at weeks 96, 
144 and 192. These included laboratory measure- 
ments of haematological function (white blood 
cell count, haemoglobin, mean corpuscular vol- 
ume, platelets) and biochemistry (urea, creati- 
nine, total protein, albumin, alanine amino- 
transferase and/or aspartate aminotransferase, 
bilirubin) and other safety data such as physical 
and neurological examinations, including 
fundoscopy. 
RESULTS 
Patient population 
A total of 155 patients (91 male, 64 female) 
entered the continuation study. At the start of the 
continuation study, 21% of the patients were 
aged 2 to ~6 years, 59% were aged 6 to ~13 and 
21% were 213 years (up to a maximum of 19 
years). From the physical and neurological 
examinations at the screening visit, 37% of 
patients had some degree of developmental 
impairment. 
Treatment 
A summary of the duration of lamotrigine 
treatment is given in Table 1. Overall, 155 
patients were treated with lamotrigine for 52-221 
weeks, of which 89 patients received lamotrigine 
for at least 144 weeks (including treatment in the 
initial study). The mean duration of treatment 
was 140 weeks. This represents 417.9 patient- 
years of experience. 
At the start of the continuation study, 57 
patients were taking one concomitant AED, 71 
were taking two, four were taking three, and one 
Table 1: Total duration of lamotrigine 
therapy (including initial 48 weeks treatment 
prior to this continuation study) 
Lamotrigine treatment 
period (weeks) 
48-72 
>72-96 
>96-120 
>120-144 
>144-168 
>168 
Number of 
patients (%) 
10 (6) 
ll(7) 
10 (6) 
3.5 (23) 
ll(46) 
18 (12) 
patient was taking four AEDs. Twenty-two 
patients were on lamotrigine monotherapy at 
entry into the continuation study. 
Study completion 
Of the 155 patients who entered the continuation 
study, 109 (70%) were considered to have 
completed the study, having been treated to 
either week 192 (14 patients) or week 144 (95 
patients). Of the 46 patients who discontinued 
prematurely, 21 patients withdrew due to lack of 
continuing benefit, six due to adverse experiences 
and the remaining 19 due to a variety of other 
reasons. 
Global seizure control 
The overall percentage of patients with an 
improvement in seizure control compared with 
the original baseline (category 5, 6 or 7) was 
maintained throughout the continuation study, 
being 80% (110/137) at week 72,76% (93/122) at 
week 96, 76% (90/119) at week 120 and 73% 
(66/91) at week 144 (Fig. 1). There were fewer 
patients .at week 168 because only one centre 
could continue lamotrigine treatment beyond 
week 144, but 89% (24/27) of these patients had 
an improvement in seizure control. Patients with 
no change in their seizure frequency accounted 
for 12% (16/137), 12% (15/122), 16% (19/119), 
23% (21/91) and 11% (3/27) patients at weeks 
72, 96, 120, 144 and 168, respectively. The 
proportion of patients with any deterioration 
(category 1,2 or 3) in seizure frequency was low, 
being between 5 and 11% throughout the 
continuation study. \ 
For 19 patients, the investigator recorded 
subjective comments regarding seizure control. 
These comments indicated beneficial effects of 
lamotrigine treatment on behaviour, alertness, 
seizure severity, quality of life and mobility. Some 
of these reports were in patients where lamo- 
trigine treatment was continued in the absence of 
a significant effect on seizure frequency. 
Lamotrigine dose and concomitant antiepileptic 
drugs 
Analysis of the minimum and maximum daily 
doses of lamotrigine, taking into account con- 
comitant AED therapy at the screening visit, 
provided an indication of the optimal daily dose 
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Fig. 1: Global evaluation of seizure control during long-term lamotrigine therapy (relative to screening visit prior to initiation of 
lamotrigine treatment in initial study). H, Marked improvement; H, moderate improvement, 0, mild improvement; n , no 
change; W, any deterioration (all categories). 
of lamotrigine in each patient subgroup. In the 68 
patients who received AED co-medication which 
did not include sodium valproate, 5- 
15 mg/kg/day might be considered to be the 
optimum daily dose of lamotrigine, because the 
minimum and maximum dosages were within this 
range in the majority of patients (66 and 74%, 
respectively). This is in comparison to a likely 
optimum daily lamotrigine dose of approximately 
l-5 mg/kg/day in patients receiving a 
concomitant AED regimen which included 
sodium valproate, because this was the minimum 
and maximum dosage in 56 and 47% of patients, 
respectively. However, 27 (42%) of patients 
taking concomitant sodium valproate had a 
maximum lamotrigine dose of >5 mg/kg/day. 
There was no evidence that either concomitant 
AEDs or weight changes during the study were 
responsible for the high number of patients in this 
group. 
At least one AED was withdrawn from the 
medication of 30 patients during the study and in 
14 cases this resulted in a permanent reduction in 
the number of AEDs. Four of these patients were 
maintained on lamotrigine monotherapy and a 
further eight patients were treated with lamo- 
trigine monotherapy at some time. Of the 
22 patients who entered the continuation study 
on lamotrigine monotherapy, 13 remained so 
throughout the duration of the study. In total, 34 
patients received lamotrigine monotherapy dur- 
ing the continuation study. Eighteen of these 
received lamotrigine monotherapy for at least 
one year and a further four patients were treated 
with lamotrigine monotherapy for at least three 
years. 
The majority of patients were considered to 
have excellent compliance with the lamotrigine 
dosage regimen at each scheduled evaluation 
period of the study. The proportion of patients 
assessed as being 100% compliant ranged from 
81% (at week 144) to 89% (at weeks 48, 96 and 
168). 
Adverse experiences and safety evaluation 
Eighty-three patients (54%) reported 176 adverse 
experiences after the screening visit for the 
continuation study. Twelve adverse experiences 
were reported by more than three patients (Table 
2) in the continuation study. The majority (63%) 
of adverse experiences were classified as being 
mild in intensity. 
Only six patients (4%) withdrew from the study 
because of an adverse experience. These were: 
persistence of a rash which had developed during 
the initial study; aggression and confusion; 
Table 2: Adverse experiences reported in more 
than three patients 
Adverse experience Number of patients (%) 
Aggravated reaction* 
Infection 
Unevaluable reactiont 
Pharyngitis 
Somnolence 
Ear disorder 
22 (14) 
13 (8) 
8 (5) 
7 (5) 
7 (5) 
6 (4) 
Rhinitis 6 (4) 
Headache 5 (3) 
Rash 5 (3) 
Vomiting 5 (3) 
Accidental injury 4 (3) 
Abdominal pain 4 (3) 
* Aggravated reaction includes increased seizure 
frequency or severity, prolonged seizures and status 
epilepticus. 
t Unevaluable reaction refers to experiences which 
could not be coded and were hospitalization for 
oximetry; irritability; decreased mobility; dental 
treatment: bilateral femoral rotation osteotomy; 
increase of mucous; increase of mucous secretion; 
callosotomy; and adrenotonsillectomy. 
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moderate paraesthesia in the legs; an increase in 
seizures; death attributed to sudden unexplained 
death in epilepsy (SUDEP); and death shortly 
after a seizure thought to be due to aspiration of 
gastric contents. Only the rash was considered, by 
the investigator, to be related to lamotrigine 
treatment, in the other cases the causality was 
considered to be either not related (two cases) or 
unknown (three cases). 
Lamotrigine had no effect on the distribution of 
height and weight measurements throughout 
either the initial 12-month study or the subse- 
quent continuation study (Tables 3 and 4). No 
physical or neurological abnormalities occurred 
during the continuation study which had not been 
reported at the screening visit. There were no 
clinically significant abnormal laboratory test 
results. 
DISCUSSION AND CONCLUSIONS 
The clinical efficacy of lamotrigine as add-on 
therapy for treatment-resistant epilepsy in chil- 
dren has previously been demonstrated in open 
12-month studies in patients with a broad range of 
seizure typesG9. In this continuation study, the 
long-term efficacy of lamotrigine was assessed by 
a global evaluation of seizure control given by the 
investigator relative to the period prior to 
initiation of lamotrigine therapy. Although less 
objective than seizure counts, global assessments 
are more clinically appropriate for long-term 
analyses in view of the difficulty in continuing to 
count seizures on a daily basis over long periods 
of time. In the initial 1Zmonth study, global 
evaluations of seizure control showed that 69% of 
patients had an improvement at week 12 and 74% 
at week 48’. In this continuation study, this level 
of seizure control was maintained. Improvement 
in seizure control relative to a three-month period 
prior to initiation of lamotrigine therapy was 
achieved in 80% of patients after 72 weeks of 
treatment and this was generally maintained, with 
73% of patients assessed as having an improve- 
ment after 144 weeks of lamotrigine treatment. 
Table 3: Comparison of height measurements with age- 
specific percentile 
Cede range Number of patients (%) 
Screen Week 48 Week 96 Week 144 
250% Sl(42) 56 (41) 41(35) 29 (35) 
3-49% 68 (50) 69 (50) 61(52) 42 (51) 
53% 1163) 13 (9) 15 (13) ll(l4) 
Table 4: Comparison of weight measurements with age- 
specific percentile 
Centile range Number of patients (%) 
Screen Week 48 Week 96 Week 144 
250% 74 (48) 66 (43) 55 (43) 39 (46) 
3-49% 63 (41) 68 (45) 55 (43) 34 (41) 
53% 17 (11) 19 (12) 17 (14) 11(13) 
Few patients withdrew from the study due to lack 
of continuing benefit, suggesting that lamotrigine 
provides good long-term maintenance of seizure 
control. It is noteworthy that the long-term 
maintenance of seizure control was achieved in a 
population of children with relatively severe 
epilepsy. 
Pharmacokinetic studies in children, as in 
adults, show that the rate of elimination of 
lamotrigine is influenced by some AEDs’. The 
recommended maintenance doses of lamotrigine 
in children receiving other AEDs including 
(l-5 mg/kg/day) or excluding (5-15 mg/kg/day) 
sodium valproate” were confirmed during this 
study. The dose of lamotrigine was adjusted as 
required in order to maximize efficacy or mini- 
mize adverse experiences. In almost half of the 
patients taking sodium valproate, this resulted in 
a daily lamotrigine dose of >5 mg/kg/day. There 
was no evidence of any relationship between the 
lamotrigine dose and any additional AED in the 
group receiving sodium valproate (that is the 
presence or absence of any hepatic enzyme- 
inducing drugs). This suggests that further im- 
provements in seizure control may be obtained 
with higher doses of lamotrigine. There was no 
evidence of an increase in the required main- 
tenance dose of lamotrigine in the long-term. 
Long-term tolerability of AEDs in children is 
important, because the adverse event profile of 
the drug is often a major determinant in the 
choice of therapy”. This continuation study has 
shown that the favourable safety profile of 
lamotrigine that was observed in the initial 
1Zmonth study’ is maintained in the long-term. 
As in previous studies in children, the most 
common adverse experiences included an in- 
crease in frequency or severity of seizures 
(aggravated reactions) and typical childhood 
illnesses, particularly infections. These are con- 
sistent with the expected fluctuations in seizure 
control and general health of this population of 
paediatric patients with treatment-resistant epi- 
lepsy. There was no evidence of the emergence of 
adverse intellectual or cognitive effects as a result 
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of lamotrigine therapy. Indeed, several inves- 
tigators spontaneously reported subjective im- 
provements in alertness, behaviour, seizure sev- 
erity, quality of life and mobility in a number of 
children in this study. This is consistent with 
previously published observations in children 
taking lamotrigine12. In addition, lamotrigine did 
not appear to affect normal growth. 
Non-compliance with AEDs, often as a result 
of side-effects, is considered to be one of the main 
causes of treatment failure13. Lack of compliance 
with AED therapy has been reported in as many 
as 2575% of paediatric patients”. The high 
degree of compliance observed in this study and 
the low rate of withdrawal due to adverse 
experiences appear to confirm the good long-term 
tolerability of lamotrigine. 
In conclusion, seizure control was maintained 
for up to a total of four years of treatment with 
lamotrigine in paediatric patients with treatment- 
resistant epilepsy. Lamotrigine was we11’tolerated 
during long-term therapy with the majority of 
adverse experiences being mild in intensity and 
not necessitating the withdrawal of lamotrigine 
therapy. There was no evidence of any de- 
leterious effect on the growth of the children. 
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